- Home
- MIRM vs MHF Comparison
MIRM vs MHF Comparison
Compare MIRM & MHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MHF
- Stock Information
- Founded
- MIRM 2018
- MHF 1988
- Country
- MIRM United States
- MHF United States
- Employees
- MIRM N/A
- MHF N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MHF Finance/Investors Services
- Sector
- MIRM Health Care
- MHF Finance
- Exchange
- MIRM Nasdaq
- MHF Nasdaq
- Market Cap
- MIRM 2.5B
- MHF 150.6M
- IPO Year
- MIRM 2019
- MHF N/A
- Fundamental
- Price
- MIRM $52.66
- MHF $7.03
- Analyst Decision
- MIRM Strong Buy
- MHF
- Analyst Count
- MIRM 9
- MHF 0
- Target Price
- MIRM $66.22
- MHF N/A
- AVG Volume (30 Days)
- MIRM 456.2K
- MHF 57.2K
- Earning Date
- MIRM 08-06-2025
- MHF 01-01-0001
- Dividend Yield
- MIRM N/A
- MHF 4.29%
- EPS Growth
- MIRM N/A
- MHF N/A
- EPS
- MIRM N/A
- MHF N/A
- Revenue
- MIRM $379,251,000.00
- MHF N/A
- Revenue This Year
- MIRM $35.83
- MHF N/A
- Revenue Next Year
- MIRM $16.83
- MHF N/A
- P/E Ratio
- MIRM N/A
- MHF N/A
- Revenue Growth
- MIRM 69.31
- MHF N/A
- 52 Week Low
- MIRM $36.17
- MHF $5.92
- 52 Week High
- MIRM $54.23
- MHF $6.79
- Technical
- Relative Strength Index (RSI)
- MIRM 64.66
- MHF 57.96
- Support Level
- MIRM $49.22
- MHF $7.01
- Resistance Level
- MIRM $53.86
- MHF $7.18
- Average True Range (ATR)
- MIRM 1.57
- MHF 0.10
- MACD
- MIRM 0.08
- MHF 0.04
- Stochastic Oscillator
- MIRM 79.63
- MHF 86.11
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.